DiaMedica Therapeutics (NASDAQ:DMAC) Upgraded by Zacks Investment Research to Buy

DiaMedica Therapeutics stock has undergone multiple analysts rating changes in the recent past.  DiaMedica Therapeutics Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of DiaMedica Therapeutics traded up $0.07 on Tuesday, reaching $4.07. 0 shares of the stock traded hands, compared to its average volume of 226982. Shares of DiaMedica Therapeutics were trading at $4.07 on Tuesday. The firm’s 50 day moving average is $3.86 and its 200 day moving average is $7.01.DiaMedica Therapeutics has a 12 month low of $4.00 and a 12 month high of $10.88. While on yearly highs and lows, DiaMedica Therapeutics’s today has traded high as $4.11 and has touched $4.00 on the downward trend. See More Analyst Rating at: RATING

DiaMedica Therapeutics Earnings and What to expect: 

DiaMedica Therapeutics last released its quarterly earnings data on August 11th, 2021. The reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. DiaMedica Therapeutics has generated ($0.78) earnings per share over the last year (($0.78) diluted earnings per share). Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.80) to ($1.21) per share. DiaMedica Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 3rd, 2021 based off prior year’s report dates.

Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.80) to ($1.21) per share. The P/E ratio of DiaMedica Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of DiaMedica Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. DiaMedica Therapeutics has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

DiaMedica Therapeutics (NASDAQ:DMAC) Moving Average Technical Analysis

5 day Moving Average is $3.99 And 5 day price change is $0.13 (3.30%)  with average volume for 5 day average is 71,680. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.01 and 20 day price change is $0.44 (12.12%) and average 20 day moving volume is 215,715. 50 day moving average is $3.86  and 50 day price change is $0.54 ( 15.30%)  and with average volume for 50 days is : 222,784. 200 day moving average is $7.01  and 200 day price change is -$5.57 (-57.78%)  and with average volume for 200 days is : 206,731.

Other owners latest trading in DiaMedica Therapeutics :

  • On 8/25/2021 shares held by Marshall Wace LLP were 155,662 which equates to market value of $0.69M and appx 0.00% owners of DiaMedica Therapeutics
  • On 8/23/2021 shares held by Morgan Stanley were 23,627 which equates to market value of $0.11M and appx 0.00% owners of DiaMedica Therapeutics
  • On 8/17/2021 shares held by Millennium Management LLC were 20,690 which equates to market value of $92K and appx 0.00% owners of DiaMedica Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 18.68% for DiaMedica Therapeutics

See More Analyst Rating at: RATING